Keybanc analyst Brandon Nispel downgrades T-Mobile US (NASDAQ:TMUS) from Overweight to Sector Weight.
SVB Leerink Maintains Outperform on Mirati Therapeutics, Lowers Price Target to $75
SVB Leerink analyst Andrew Berens maintains Mirati Therapeutics (NASDAQ:MRTX) with a Outperform and lowers the price target from $85 to $75.